BR112023001236A2 - Polimorfos de 5-aza-4'-tio-2-desoxicitidina - Google Patents

Polimorfos de 5-aza-4'-tio-2-desoxicitidina

Info

Publication number
BR112023001236A2
BR112023001236A2 BR112023001236A BR112023001236A BR112023001236A2 BR 112023001236 A2 BR112023001236 A2 BR 112023001236A2 BR 112023001236 A BR112023001236 A BR 112023001236A BR 112023001236 A BR112023001236 A BR 112023001236A BR 112023001236 A2 BR112023001236 A2 BR 112023001236A2
Authority
BR
Brazil
Prior art keywords
deoxycytidine
aza
thio
polymorphs
crystalline polymorphs
Prior art date
Application number
BR112023001236A
Other languages
English (en)
Portuguese (pt)
Inventor
J Suto Mark
Young Jung Doo
Soo Lee Jin
Cho Hyunyong
Original Assignee
Southern Res Inst
Pinotbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst, Pinotbio Inc filed Critical Southern Res Inst
Publication of BR112023001236A2 publication Critical patent/BR112023001236A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023001236A 2020-07-23 2021-07-23 Polimorfos de 5-aza-4'-tio-2-desoxicitidina BR112023001236A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055754P 2020-07-23 2020-07-23
PCT/US2021/043021 WO2022020747A1 (en) 2020-07-23 2021-07-23 Polymorophs of 5-aza-4'-thio-2-deoxycytidine

Publications (1)

Publication Number Publication Date
BR112023001236A2 true BR112023001236A2 (pt) 2023-04-04

Family

ID=79687860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001236A BR112023001236A2 (pt) 2020-07-23 2021-07-23 Polimorfos de 5-aza-4'-tio-2-desoxicitidina

Country Status (10)

Country Link
US (1) US11447472B2 (https=)
EP (1) EP4185583A4 (https=)
JP (1) JP7679452B2 (https=)
KR (1) KR102866823B1 (https=)
CN (1) CN115989229A (https=)
AU (1) AU2021314329A1 (https=)
BR (1) BR112023001236A2 (https=)
CA (1) CA3186696A1 (https=)
MX (1) MX2023000979A (https=)
WO (1) WO2022020747A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230123277A1 (en) * 2021-10-15 2023-04-20 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease and thalassemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) * 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2011109012A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
EP3527226A4 (en) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
EP3746452B1 (en) * 2018-02-01 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Also Published As

Publication number Publication date
MX2023000979A (es) 2023-04-20
JP7679452B2 (ja) 2025-05-19
EP4185583A4 (en) 2024-10-30
CA3186696A1 (en) 2022-01-27
KR102866823B1 (ko) 2025-09-30
EP4185583A1 (en) 2023-05-31
WO2022020747A1 (en) 2022-01-27
US11447472B2 (en) 2022-09-20
AU2021314329A1 (en) 2023-02-23
AU2021314329A8 (en) 2023-03-09
JP2023535724A (ja) 2023-08-21
KR20230061354A (ko) 2023-05-08
WO2022020747A8 (en) 2023-02-16
US20220024903A1 (en) 2022-01-27
CN115989229A (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
BR112023015715A2 (pt) Inibidor de cdk
CL2023003751A1 (es) Compuestos moduladores de diacilglicerol quinasa
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
NO20074050L (no) Purinderivater som fungerer som A2A-receptoragonister
BR0316407A (pt) Derivados de nucleosìdeo antiviral
CY1106305T1 (el) Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
BR0206588A (pt) Composto, processo para produzir o mesmo, uso do mesmo, composição farmacêutica, e, método para tratar um paciente afligido com uma condição patológica suscetìvel à melhora pelo antagonismo de integrinas alfa4beta1 e/ou alfa4beta7
ECSP099465A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y métodos
AR033344A1 (es) Compuestos derivados de benzofenonas como inhibidores de la transcriptasa inversa, su uso en la fabricacion de medicamentos, intermediarios y composiciones farmaceuticas
UY30004A1 (es) Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina
BR0009884A (pt) Processos e composições para a inibição da função das sequências de polinucleotìdeos
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
BR112018075593A2 (pt) método para fabricar briquetes contendo composto de cálcio-magnésio e composto à base de ferro e briquetes desse modo obtidos
BR112023001236A2 (pt) Polimorfos de 5-aza-4'-tio-2-desoxicitidina
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
BR112022021370A2 (pt) Composto, e, método de tratamento de uma doença ou distúrbio
MX390835B (es) Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes
MX2023001324A (es) Compuestos antagonistas.
MX2024000261A (es) Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica.